
Endocrinologist

No OPD information available
Prader-Willi Syndrome
Type 1 Diabetes (T1D)
Celiac Disease
Congenital Hyperinsulinism
Growth Hormone Deficiency (GHD)
Hormone Replacement Therapy (HRT)
Hypopituitarism
Intersex
Low Blood Sugar
Malabsorption
Short Stature (Growth Disorders)
Turner Syndrome
Undescended Testicle
Geoffrey R. Ambler is a male healthcare provider who helps people with different health conditions like Prader-Willi Syndrome, Type 1 Diabetes, Celiac Disease, and more. He is skilled in treating hormone-related issues such as Growth Hormone Deficiency and Low Blood Sugar. Geoffrey also helps patients with growth disorders and other medical concerns.
Geoffrey R. Ambler uses special treatments and techniques to care for his patients. He is good at communicating with people and makes sure they understand their health conditions and treatments. Patients trust him because he listens to their concerns and provides clear explanations.
To stay updated with the latest medical knowledge, Geoffrey R. Ambler reads research articles and attends medical conferences. He works closely with other healthcare professionals to share knowledge and improve patient care. Geoffrey values teamwork and collaboration in his medical practice.
Geoffrey R. Ambler's work has positively impacted many patients' lives. He has helped children with growth hormone deficiency grow taller and feel healthier. Geoffrey's research on hormone treatments for certain conditions has also contributed to medical knowledge.
One of Geoffrey R. Ambler's notable publications is about treating a condition called Cryptorchidism in young boys. He has also conducted a clinical trial to study the effectiveness and safety of a growth hormone therapy in children.
In summary, Geoffrey R. Ambler is a dedicated healthcare provider who uses his skills and knowledge to help patients with various health conditions. He stays updated with the latest medical research, collaborates with colleagues, and makes a positive impact on his patients' lives.
Enrollment Status: Completed
Published: July 24, 2024
Intervention Type: Drug
Study Drug:
Study Phase: Phase 3
